Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549383 | 1.00 | FFAR1 (0.76) | FFAR1 | |
| SCHEMBL12021112 | 0.93 | FFAR1 (0.68) | FFAR1 | |
| SCHEMBL22992825 | 0.88 | FFAR1 (0.59) | FFAR1 | |
| SCHEMBL3550138 | 0.87 | FFAR1 (0.75) | FFAR1 | |
| SCHEMBL3550142 | 0.87 | FFAR1 (0.75) | FFAR1 | |
| SCHEMBL6104640 | 0.87 | FFAR1 (0.75) | FFAR1 | |
| SCHEMBL4736849 | 0.86 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL4736851 | 0.86 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL3518826 | 0.84 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL3524415 | 0.84 | FFAR1 (1.00) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | claimed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | claimed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | claimed |
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1893582-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2006127503-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | FFAR1 51/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | FFAR1 51/4885 |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | IAPP, INSR, GPR119 | FFAR1 931/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.